MX2024005327A - Composiciones y metodos de dsg2. - Google Patents

Composiciones y metodos de dsg2.

Info

Publication number
MX2024005327A
MX2024005327A MX2024005327A MX2024005327A MX2024005327A MX 2024005327 A MX2024005327 A MX 2024005327A MX 2024005327 A MX2024005327 A MX 2024005327A MX 2024005327 A MX2024005327 A MX 2024005327A MX 2024005327 A MX2024005327 A MX 2024005327A
Authority
MX
Mexico
Prior art keywords
methods
compositions
dsg2
disease
treating
Prior art date
Application number
MX2024005327A
Other languages
English (en)
Spanish (es)
Inventor
Shi Yin Foo
Ryan Edward Tyler
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of MX2024005327A publication Critical patent/MX2024005327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024005327A 2021-11-02 2022-11-02 Composiciones y metodos de dsg2. MX2024005327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163274707P 2021-11-02 2021-11-02
PCT/US2022/079106 WO2023081674A1 (en) 2021-11-02 2022-11-02 Dsg2 compositions and methods

Publications (1)

Publication Number Publication Date
MX2024005327A true MX2024005327A (es) 2024-05-21

Family

ID=84569745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005327A MX2024005327A (es) 2021-11-02 2022-11-02 Composiciones y metodos de dsg2.

Country Status (12)

Country Link
US (1) US20240279304A1 (enExample)
EP (1) EP4426430A1 (enExample)
JP (1) JP2024540220A (enExample)
KR (1) KR20240110819A (enExample)
CN (1) CN118369351A (enExample)
AR (1) AR127555A1 (enExample)
AU (1) AU2022382972A1 (enExample)
CA (1) CA3236070A1 (enExample)
IL (1) IL312219A (enExample)
MX (1) MX2024005327A (enExample)
TW (1) TW202334190A (enExample)
WO (1) WO2023081674A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860721A (zh) * 2023-12-25 2024-04-12 五邑大学 三甲基氯化铵在制备冠状病毒刺突蛋白受体结合结构域的特异性结合剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965197A (en) 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
DK2147104T3 (en) 2007-05-21 2015-12-14 Danisco Us Inc USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION
US8324578B2 (en) 2008-09-30 2012-12-04 Apple Inc. Hidden sensors in an electronic device
KR101410845B1 (ko) 2009-09-10 2014-06-23 바이오콘 리미티드 새로운 프로리파제-보바인 트립시노겐 융합 단백질
JP2012107935A (ja) * 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Ｄｅｓｍｏｇｌｅｉｎ−２蛋白質による脳梗塞の検査方法
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
EP3568697B1 (en) * 2017-01-13 2022-06-29 The Hospital for Sick Children Method for diagnosis of arrhythmogenic right ventricular cardiomyopathy
CA3202364A1 (en) * 2020-12-15 2022-06-23 Arvada Therapeutics, Inc. Dsg2 compositions and methods for the treatment of covid-19

Also Published As

Publication number Publication date
KR20240110819A (ko) 2024-07-16
EP4426430A1 (en) 2024-09-11
TW202334190A (zh) 2023-09-01
CA3236070A1 (en) 2023-05-11
AR127555A1 (es) 2024-02-07
WO2023081674A1 (en) 2023-05-11
JP2024540220A (ja) 2024-10-31
AU2022382972A1 (en) 2024-05-09
US20240279304A1 (en) 2024-08-22
CN118369351A (zh) 2024-07-19
IL312219A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
ZA202001564B (en) Anti- folate receptor alpha antibody conjugates and their uses
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
MX2020001167A (es) Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide.
MX2025000574A (es) Conjugado anticuerpo-farmaco, metodo de preparacion y uso del mismo
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
PH12022550392A1 (en) Compositions and methods of treating vascular diseases
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
MX2021005077A (es) Peptidos y composiciones farmaceuticas para tratar enfermedades oculares.
JOP20200265A1 (ar) متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 (glp-1) واستخداماتها
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MX2021012129A (es) Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
MX2024000701A (es) Metodos de tratamiento de la enfermedad de alzheimer.
WO2017181193A3 (en) Methods and compounds for stimulating read-through of premature termination codons
PH12017501312A1 (en) Method for producing hop extract
SG11201900810WA (en) Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
WO2020163493A3 (en) Materials and methods for treating a neurodegenerative disease
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.